ArticleBlood cancer journal2018
Differences in genomic abnormalities among African individuals with monoclonal gammopathies using calculated ancestry.
Article in Blood cancer journal, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed, 1 synthesis or guideline pooled it, 63 citations in OpenAlex.
- Population genetic considerations for using biobanks as international resources in the pandemic era and beyond.BMC genomics · 2021Pooled it
- Race-Dependent Differences in Risk, Genomics, and Epstein-Barr Virus Exposure in Monoclonal Gammopathies: Results of SWOG S0120.Clinical cancer research : an official journal of the American Association for Cancer Research · 2020Trial
- Genomic Features Do Not Account for Differences in Multiple Myeloma Risk by Ancestry.Blood cancer discovery · 2026Article
- Translocation t(11;14) and BCL2-inhibition in multiple myeloma.Haematologica · 2026Review
- Analysis of Social Drivers of Health, Race, and Ethnicity With Survival in Myeloma Patients.Clinical lymphoma, myeloma & leukemia · 2026Article
- Differential life expectancies and life years lost associated with multiple myeloma in the United States: a simulation modeling study.The oncologist · 2026Article
- Equal survival for Black Americans with multiple myeloma when appropriately matched to White Americans.Blood cancer journal · 2025Article
- Monoclonal Gammopathies in Africa.Clinical lymphoma, myeloma & leukemia · 2025Review
- AncestryGeni: a novel genetic ancestry classification pipeline for small and noisy sequence data.Bioinformatics (Oxford, England) · 2025Article
- Addressing Health Disparities in Hematologic Malignancies: from Genes to Outreach.Blood cancer discovery · 2025Review
- FaMMily Affairs: Dissecting inherited contributions to multiple myeloma risk.Seminars in hematology · 2025Review
- Population differences in the associations between chromosomal abnormalities and overall survival of multiple myeloma.Blood neoplasia · 2025Article
- Global disparities in drug-related adverse events of patients with multiple myeloma: a pharmacovigilance study.Blood cancer journal · 2024Article
- Addressing the disparities: the approach to the African American patient with multiple myeloma.Blood cancer journal · 2023Review
- Partnering With All Patients: Ensuring Shared Decision Making and Evidence-Based Management for Underrepresented Groups With Multiple Myeloma.American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting · 2023Article
- Disparity in the detection of chromosome 15 centromere in patients of African ancestry with a plasma cell neoplasm.Genetics in medicine open · 2023Article
- Immunophenotypic expression profile of multiple myeloma cases at a tertiary hospital in Nairobi Kenya.Frontiers in medicine · 2023Article
- Principal Component Analyses (PCA)-based findings in population genetic studies are highly biased and must be reevaluated.Scientific reports · 2022Article
- Distribution of clonal hematopoiesis of indeterminate potential (CHIP) is not associated with race in patients with plasma cell neoplasms.Blood cancer journal · 2022Article
- Differences in the cytogenetic underpinnings of AL amyloidosis among African Americans and Caucasian Americans.Blood cancer journal · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors at 5 institutions in 2 countries.
Funding
Abstract
Multiple myeloma (MM) is two- to three-fold more common in African Americans (AAs) compared to European Americans (EAs). This striking disparity, one of the highest of any cancer, may be due to underlying genetic predisposition between these groups. There are multiple unique cytogenetic subtypes of MM, and it is likely that the disparity is associated with only certain subtypes. Previous efforts to understand this disparity have relied on self-reported race rather than genetic ancestry, which may result in bias. To mitigate these difficulties, we studied 881 patients with monoclonal gammopathies who had undergone uniform testing to identify primary cytogenetic abnormalities. DNA from bone marrow samples was genotyped on the Precision Medicine Research Array and biogeographical ancestry was quantitatively assessed using the Geographic Population Structure Origins tool. The probability of having one of three specific subtypes, namely t(11;14), t(14;16), or t(14;20) was significantly higher in the 120 individuals with highest African ancestry (≥80%) compared with the 235 individuals with lowest African ancestry (<0.1%) (51% vs. 33%, respectively, p value = 0.008). Using quantitatively measured African ancestry, we demonstrate a major proportion of the racial disparity in MM is driven by disparity in the occurrence of the t(11;14), t(14;16), and t(14;20) types of MM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.